Haifeng Lin

630 total citations
32 papers, 303 citations indexed

About

Haifeng Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Haifeng Lin has authored 32 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Surgery. Recurrent topics in Haifeng Lin's work include Lung Cancer Diagnosis and Treatment (8 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Haifeng Lin is often cited by papers focused on Lung Cancer Diagnosis and Treatment (8 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Haifeng Lin collaborates with scholars based in China, Mongolia and Greece. Haifeng Lin's co-authors include Mingyue Zhu, Mengsen Li, Haiqing Zhang, Yang Qu, Kun Li, Zhiming Zeng, Chengsheng Zhang, Chen Zhang, Li‐Hua Yang and Xiaohong Zhuang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Haifeng Lin

31 papers receiving 301 citations

Peers

Countries citing papers authored by Haifeng Lin

Since Specialization

Citations

This map shows the geographic impact of Haifeng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haifeng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haifeng Lin more than expected).

Fields of papers citing papers by Haifeng Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haifeng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haifeng Lin. The network helps show where Haifeng Lin may publish in the future.

Co-authorship network of co-authors of Haifeng Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Haifeng Lin. A scholar is included among the top collaborators of Haifeng Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haifeng Lin. Haifeng Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning 2025 ·npj Precision Oncology ·Yongmeng Li, Xiaodong Chai, Ming Yang, Jian Xiong, Junfeng Zeng, Yun Chen, Gang Xu, Haifeng Lin, Wei Wang, Shuhao Wang, Nanying Che	1
2	IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells 2024 ·Annals of Hepatology ·(unknown), (unknown), (unknown), Jinchen Liu, Haifeng Lin, Bo Lin, Wei Li, Mingyue Zhu, Mengsen Li	1
3	Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers 2024 ·Clinical Medicine Insights Oncology ·Kun Li, Nana Zhang, (unknown), (unknown), Dan Zhao, (unknown), Jing Mu, Haifeng Lin, (unknown), (unknown), Bo Yu, (unknown), Yanrong Wang, Dongxing Zhang, (unknown), (unknown)	3
4	Influence of parity on weight gain during pregnancy in women with Gestational Diabetes: A retrospective cohort study 2024 ·Pakistan Journal of Medical Sciences ·Lin Lin, Ruiyun Chen, Haifeng Lin, Ting Yao, (unknown), (unknown)	0
5	Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study 2023 ·The Oncologist ·Chengsheng Zhang, Zhiming Zeng, (unknown), (unknown), Xiaohong Zhuang, (unknown), (unknown), (unknown), Haifeng Lin	14
6	Gasdermin E mediates pyroptosis in the progression of hepatocellular carcinoma: a double-edged sword 2023 ·Gastroenterology report ·Yan Lu, (unknown), Haifeng Lin, Mingyue Zhu, Mengsen Li	4
7	Integrative pan-cancer analysis reveals the importance of PAQR family in lung cancer 2023 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Shu Min Lin, Xin Xing, (unknown), Haifeng Lin	2
8	Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells 2023 ·SHILAP Revista de lepidopterología ·Qiuyue Zhang, (unknown), Haifeng Lin, Bo Lin, Mingyue Zhu, Mengsen Li	10
9	Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma. 2022 ·Journal of Clinical Oncology ·Haifeng Lin, (unknown), (unknown), Chengsheng Zhang, (unknown), (unknown), Zhiming Zeng, Li‐Hua Yang	3
10	IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma 2021 ·Frontiers in Oncology ·(unknown), Haifeng Lin, (unknown), Mingyue Zhu, Mengsen Li	152
11	909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results 2021 ·Annals of Oncology ·Xiangchuan Chen, Chaosu Hu, (unknown), (unknown), Jixia Li, (unknown), (unknown), Yi Jiang, Yan Sun, Liangfang Shen, (unknown), Guorong Zou, (unknown), Yu Wang, Shaojun Lin, (unknown), (unknown), Rui‐Hua Xu, Haifeng Lin, Ruojun Wang	5
12	Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma. 2021 ·Journal of Clinical Oncology ·Haifeng Lin, (unknown), (unknown), Chengsheng Zhang, (unknown), (unknown), Zhiming Zeng, Li‐Hua Yang	6
13	<p>Variants of <em>MIR137HG</em> Genes are Associated with Liver Cancer Risk in Chinese Li Population</p> 2020 ·OncoTargets and Therapy ·Chaoying Wang, (unknown), (unknown), (unknown), (unknown), Chengsheng Zhang, (unknown), (unknown), Haifeng Lin, Wenjun Tang	5
14	Performance of the MeltPro MTB Assays in the Diagnosis of Drug-Resistant Tuberculosis Using Formalin-Fixed, Paraffin-Embedded Tissues 2020 ·American Journal of Clinical Pathology ·Jing Mu, Zichen Liu, Chen Zhang, (unknown), Weili Du, Haifeng Lin, Kun Li, Jing Song, Nanying Che, Honggang Liu	7
15	Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer 2019 ·PeerJ ·(unknown), (unknown), Wenjun Tang, (unknown), Minghua Wang, Haifeng Lin, Hong Guo, Yuling Ma, Jun Zhang, Qin Li	13
16	Association between IL‐1R2 polymorphisms and lung cancer risk in the Chinese Han population: A case–control study 2019 ·Molecular Genetics & Genomic Medicine ·Chaoying Wang, Chengsheng Zhang, (unknown), (unknown), Jie Wang, Hui Liu, (unknown), Zhong Chen, Haifeng Lin	6
17	Cribriform pattern in lung invasive adenocarcinoma correlates with poor prognosis in a Chinese cohort 2018 ·Pathology - Research and Practice ·Yang Qu, Haifeng Lin, Chen Zhang, Kun Li, Haiqing Zhang	14
18	Association of plasma apolipoprotein CIII, high sensitivity C-reactive protein and tumor necrosis factor-α contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China 2018 ·Lipids in Health and Disease ·Lin Chen, (unknown), Hui Liu, (unknown), Tiansong Wang, (unknown), (unknown), Haifeng Lin, (unknown), (unknown)	8
19	Remote ischaemic preconditioning reduces acute kidney injury in adult patients undergoing cardiac surgery with cardiopulmonary bypass: a meta-analysis 2016 ·European Journal of Cardio-Thoracic Surgery ·Bin Yi, Xiang Chen, Han Shi, Tiao Lin, Haifeng Lin, (unknown), Jian Rong	5
20	Study on the intensive lipid-lowering therapy in improving the prognosis of stroke and reducing relapse rate 2013 ·Zhongguo jiceng yiyao ·Haifeng Lin, (unknown), Mingzhu Chen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact